cells, whereas a-and d-cells were negative. Exposure of isolated islets to hyperglycemia augmented ALDOB expression. The minor allele of the ALDOB variant rs550915 associated with significantly higher levels of C-peptide and insulin during OGTT and hyperglycemic clamp, respectively.
Conclusion:
Our analyses suggest that increased ALDOB expression in human islets is associated with lower insulin secretion. (J Clin Endocrinol Metab 103: [4373] [4374] [4375] [4376] [4377] [4378] [4379] [4380] [4381] [4382] [4383] 2018) A ppropriate insulin secretion and b-cell mass are prerequisites of the maintenance of glucose homeostasis. Insufficient insulin secretion is considered the ultimate cause for development of type 2 diabetes mellitus (1, 2) . To date, multiple changes have been implicated in the development of insulin deficiency. The most prominent concepts involve defective insulin secretion, insufficient adaptation of insulin synthesis, reduced b-cell mass, and increased a-cell mass with inappropriate high glucagon secretion. These changes are triggered by metabolic stress factors (i.e., hyperglycemia, hyperlipidemia, and other factors from the diabetogenic milieu) (3) . Obesity accentuates metabolic stress and, when accompanied by a genetic predisposition, accelerates the development of type 2 diabetes mellitus. Several of the diabetes-associated single nucleotide polymorphisms (SNPs) are located within genes essential for islet function (4, 5) .
Considerable efforts have been undertaken to decipher expressional changes in whole islets and individual islet cells (b-, a-, and d-cells) in association with hyperglycemia and type 2 diabetes (6-10). Some of the genes differentially altered in type 2 diabetic islets are involved in glucose metabolism (SLC2A2), Ca 2+ trafficking (TMEM37) mitochondrial metabolism (GPD2 and FXYD2), cell cycling (P21/CIP), and fatty acid (FFAR4), insulin (IR), and IGF-1 (IGF1R) receptor signaling (6) (7) (8) 11) . Most human islets used for scientific purposes are obtained from deceased organ donors. In these studies, a potential bias could arise from post mortem alteration of mRNA levels. Furthermore, human islets and consequently the RNA preparations are usually analyzed after enzymatic digestion of pancreatic tissue. Although the enzymatic isolation of cells allows the separation of islets from exocrine tissue and their dissociation into single cells, such procedures are known to alter unstable mRNAs. Indeed, considerable differences between the expression profile of human type 2 diabetic islets isolated enzymatically or by laser capture microdissection (LCM) have been discussed recently (11) . Specifically, LCMcollected islet tissue from patients with type 2 diabetes displayed lower mRNA levels of inflammatory markers and increased levels of ALDOB and FAIM2 mRNA compared with enzyme-digested, isolated type 2 diabetic islets. The current study conducted a direct comparison between expressional changes in human islet tissue and in vivo insulin secretion. This goal was achieved by assessing the in vivo secretory capacity of insulin via a hyperglycemic clamp, a procedure that circumvents potential changes in blood glucose triggered by other mechanisms (i.e., peripheral glucose handling). Glucagon-like peptide 1 (GLP-1) and arginine infusion on top of the hyperglycemic clamp further allows the evaluation of maximal secretory capacity.
Materials and Methods

Human pancreas biobank
Patients (n = 18) undergoing elective surgery for removal of operable pancreatic tumors participated in this ongoing study after providing written informed consent. For each patient, a brief clinical history was obtained. Fasting blood samples were collected prior to anesthesia and pancreatic surgery to assess metabolic traits. Tumor-free pancreatic tissue was dissected from surgical resections by a trained pathologist. The collection of human material and the study were approved by the Ethics Commission of the Medical Faculty of the University of Tuebingen (#697/2011BO1 and #355/2012BO2). Classification of normal glucose tolerance, prediabetes, or diabetes was performed according to clinical history and fasting glucose and HbA 1c levels using criteria of the American Diabetes Association (12) . Clinical characteristics of the patients are summarized in Supplemental Table 1 .
Isolation of pancreatic islet tissue by LCM
Islet tissue was isolated using a protocol previously described (11) . Briefly, the freshly resected pancreatic tissue was embedded in cryomolds containing Tissue-Tek O.C.T. compound (Sakura Finetek GmbH, Staufen, Germany). The cryomolds were frozen in isopropyl alcohol precooled in a dry ice-ethanol mixture and stored at 280°C. For the LCM procedure, pancreatic slices (10-mm thick) were dehydrated in ethanol, incubated in xylene, and air dried for 5 minutes. The laser microdissection of islet tissue was performed with a PALM MicroBeam (Zeiss, Oberkochen, Germany). Islets of Langerhans were identified by means of autofluorescence. Islet area was selected with the "freehand" selection tool and microdissected using the laser beam. Islet tissue from 40 dehydrated cryosections/pancreatic samples was lysed in 100 mL extraction buffer (Arcturus Pico pure RNA isolation kit; Applied Biosystems, Foster City, CA) and the supernatant stored at 280°C.
RNA extraction and amplification
Total RNA of islet tissue from 18 patients was isolated using the same protocol as previously described using a commercial kit (Arcturus Pico pure RNA isolation kit) (7, 11) . RNA integrity numbers were determined using a bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA samples with RNA integrity numbers .6.0 were processed in transcriptome analyses.
Transcriptome analysis
Affymetrix microarray
For this analysis, 10 to 25 ng of total RNA was amplified using the Ovation RNA Amplification System V2 and subsequently labeled with Biotin using the Encore™ Biotin Module (NuGEN Technologies, San Carlos, CA). The length distribution of the amplified cDNA products was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies). Hybridization of biotin-labeled cDNA to Affymetrix HG_U133Plus2.0 GeneChip microarrays (Affymetrix, Santa Clara, CA) was performed at ATLAS Biolabs GmbH (Berlin, Germany) as described in Solimena et al. (11) .
Laboratory measurements and assessment of b-cell function in vivo
Fasting venous blood samples were obtained prior to pancreatic surgery. Glucose levels were measured using the hexokinase method. Plasma insulin and C-peptide were determined by an immunoassay with the ADVIA Centaur XP Immunoassay System (Siemens Healthineers, Eschborn, Germany). HbA 1c measurements were performed using the Tosoh glycohemoglobin analyzer HLC-723G8 (Tosoh Bioscience, Tokyo, Japan). b-cell function was computed from fasting glucose and C-peptide levels with the updated homeostasis model assessment (HOMA2) (13) . Insulin secretion was expressed with the %B index adjusted for insulin resistance, also calculated as HOMA2 index (HOMA2-IR).
Immunohistochemistry
Paraffin-embedded, pancreatic serial sections from 12 to 17 patients were incubated with primary antibodies against insulin (1:1000; A0564; Dako, Carpinteria, CA) and glucagon (1:600; #13091; Santa Cruz Biotechnology, Santa Cruz, CA). The specific antibody binding was visualized using the Opti-View amplification system (Multimer Technology; Roche-Ventana, Tucson, AZ). Hematoxylin-eosin was used as counterstaining. Insulin-and glucagon-positive stained areas were used for quantification of a-and b-cell areas within the islets using the ImageJ software (National Institutes of Health, Bethesda, MD).
For immunofluorescence and confocal microscopy, the pancreatic sections and cultured human islet cells from organ donors were incubated with primary antibodies against insulin (1:200; mouse, #8304; Abcam, Cambridge, MA), glucagon (1:500; mouse, #10988; Abcam), somatostatin (1:1000; mouse, 14-9751-80; Invitrogen, Carlsbad, CA), and aldolase B (1:100; rabbit, #18065-1-AP; Proteintech, Rosemont, IL). The primary antibodies were visualized with goat anti-rabbit IgG-Alexa Fluor 488 (for aldolase B) and goat anti-mouse IgG-Alexa Fluor 546 (for insulin, glucagon, and somatostatin). Nuclei were stained with TO-PRO3.
Human subjects of the cross-sectional validation cohort (Tuebingen Family cohort) and hyperglycemic clamp study
The Tuebingen Family (TUEF) study currently includes .3000 healthy subjects from Southern Germany with an increased risk for type 2 diabetes as determined by a family history of diabetes, an impaired fasting glycemia, a body mass index (BMI) $27 kg/m 2 , and/or previous gestational diabetes (14) . From this study, 2645 participants with complete data sets of anthropometric assessment (sex, age, and BMI) and fivepoint oral glucose tolerance test (OGTT) including glucose, insulin, C-peptide measurements, and genotypes were selected for association analysis. In the hyperglycemic clamp study, participants underwent hyperglycemic clamps at 10 mM glucose with a stepwise GLP-1 infusion and an arginine bolus, as described earlier (15, 16) . Genotyped participants were evaluated in the current analyses (n = 70). Both studies adhered to the Declaration of Helsinki and were approved by the Ethics Committee of the Eberhard Karls University of Tuebingen. Written informed consent was obtained from all participants.
Genotyping, association analysis, and data from open-access repositories
The TUEF participants were genotyped on a genome-wide scale using Illumina's Infinium® Global Screening Array-24 v1.0 BeadChip (Illumina, San Diego, CA) which was developed based on phase 3 data of the 1,000 Genomes Project and depicts 700,078 SNPs. Within the genomic region of ALDOB including 2 kb of 5 0 -flanking sequence, 21 SNPs were identified on the array. Among these SNPs, only two, rs550915 and rs533017, revealed minor allele frequencies .0.05 and were selected for association testing due to statistical power limitations of the study population. Both SNPs were successfully genotyped (call rates .99%), in the Hardy-Weinberg equilibrium (P $ 0.4), and nonlinked (R 2 = 0.34). Publicly available genotype-phenotype association data were accessed via the Type 2 Diabetes Knowledge Portal (accessed 16 March 2018; http://www.type2diabetesgenetics.org/variantInfo/ variantInfo/rs550915#). We interrogated the Genotype-Tissue Expression (GTEx) project database for information on the association of a SNP of interest with gene transcription (17) . Single-cell RNA-sequencing data in islet cells were analyzed from data shared from the work of Enge et al. (18) .
Culture of isolated human islets and western blotting
Isolated human islets obtained from the European Consortium for Islet Transplantation (Geneva, Switzerland and Milan, Italy) and dispersed human islet cells (19) were cultured for 72 hours with medium change every 24 hours in CMRL1066 medium supplemented with 5, 10, 15, or 20 mM glucose, 2 mM L-glutamine, 10 mM HEPES, and 10% fetal calf serum. At the end of the culture period, the islets were lysed for western blotting, and the islet cells were used for immunostaining (19) . Protein lysates were subjected to SDS-PAGE, proteins transferred on nitrocellulose membranes (Hahnemühle, Dassel, Germany). Membranes were incubated for 1 hour in Trisbuffered saline-Tween supplemented with 5% milk, overnight with primary antibodies against aldolase B (Proteintech) or tubulin (Cell Signaling Technology, Danvers, MA), followed by 1-hour incubation with horseradish peroxidase-coupled secondary antirabbit IgG (GE Healthcare, München, Germany). Proteins were detected using ChemiDoc Touch Imaging System (Bio-Rad Laboratories, Hercules, CA). Analyses were performed using Bio-Rad Image laboratory software.
Statistics
The microarray data from the Affymetrix Human Genome Array HG_U133Plus2.0 were analyzed after quality control and normalization. Differential gene expression was tested with the limma package in R. Linear models were fitted using robust fit, and the log-fold change was determined by empirical Bayes moderation of the SEs toward a common value. For the visualization of the correlation of gene expression with clinical traits, the relationship between two variables was plotted with GraphPad Prism (GraphPad Software Inc, La Jolla, CA) and Pearson correlation coefficients are provided. All other analyses were performed in R. The evaluation of SNP association with insulin secretion indices from the OGTT [area under the curve (AUC) 0-30min C-peptide/AUC 0-30min glucose and AUC 0-120min C-peptide/AUC 0-120min glucose] was carried out by multiple linear regression analysis (least squares method) adjusted for potential confounders (sex, age, BMI and insulin sensitivity). The series of insulin levels during the hyperglycemic clamp study was analyzed with a repeated-measures ANOVA approach using sex, age, and insulin sensitivity as covariates. The genotype was modeled using additive inheritance in all tests. Values (P , 0.05) were considered statistically significant.
Results
Alterations of islet gene expression associate with HbA 1c and in vivo insulin secretion
In the mRNA microarray data, several genes showed differential expression in patients with diabetes or increased HbA 1c .6% (Supplemental Fig. 1 ). The most highly differentially expressed genes showed good correlation with previously published data (Supplemental Fig. 2 ) (11). Among the top upregulated genes (21 # log fold change $ 1; Supplemental Fig. 1 ), only aldolase B (ALDOB) and Fas apoptotic inhibitory molecule 2 (FAIM2) displayed a substantial, negative correlation with in vivo insulin secretion (expressed as HOMA2%B; Fig. 1A and 1B). Moreover, ALDOB and FAIM2 displayed a considerable positive correlation with HbA 1c (Fig. 1C  and 1D ). However, the expression level of FAIM2 (mean log 2 intensity 6.5) is much lower than that of ALDOB (mean log 2 intensity 9.7) (Fig. 1) .
Several other mRNAs, namely the glucose transporter SLC2A2 (GLUT2), the fatty acid receptor 4 (FFAR4), and two transmembrane proteins TMEM37 (Ca-channel inhibitory g subunit) and TMEM27, associated negatively with HbA 1c (Fig. 1E-1H ). These proteins are specifically expressed in b-cells and were reported to be decreased in type 2 diabetic islets (7, 11) . However, the mRNA levels of SLC2A2, FFAR4, TMEM37, and TMEM27 as well as the b-cell-specific isoform ALDOA displayed no correlation with HOMA2%B (data not shown).
ALDOB gene variation associates with insulin secretion in humans
If ALDOB plays a causal role in the impairment of insulin secretion during development of type 2 diabetes, genetic variation of ALDOB could associate with changes in insulin secretion. Therefore, we investigated the association of two ALDOB SNPs in 2645 genotyped individuals of our TUEF cohort with insulin secretion assessed from 5-point OGTT. The minor allele of rs550915 in the ALDOB gene region associated with a significantly higher insulin secretion ( Fig. 2A) . Similarly, when insulin secretion was assessed from hyperglycemic clamp to circumvent the effects of glucose handling, insulin secretion was higher in minor allele carriers of rs550915 (n = 70; Fig. 2B ). The effect was most prominent during the last phase of the clamp involving GLP-1 and arginine administration. From seven SNPs of the FAIM2 gene identified in our TUEF cohort, none was associated with alterations in insulin secretion (data not shown). These results endorse the prior assumption that ALDOB directly interferes with insulin secretion.
The expression of aldolase B in b-cells is augmented by glucose
To elucidate the cell type expressing ALDOB, pancreatic sections were immunostained for ALDOB, insulin, somatostatin, and glucagon ( Fig. 3A-3C ). In pancreatic islets from patients with HbA 1c ,6%, ALDOB immunostaining was undetectable. In tissue slices of patients with HbA 1c .6%, ALDOB was detected in some cells within the islets. The ALDOB-positive cells displayed insulin immunoreactivity and were glucagon and somatostatin negative (Fig. 3A-3C ). Of note, there was a poor overlapping between ALDOB and insulin signals, which suggests no colocalization of ALDOB and insulin within these cells (Fig. 3C and Supplemental Fig. 3A) . The same distribution pattern of ALDOB was observed in isolated human islet b-cells from organ donors upon exposure to 20 mM glucose for 48 hours (Supplemental Fig. 3B ). These results suggest that hyperglycemia induces expression of ALDOB in islet b-cells. In agreement, previous studies reported an elevation of AldoB mRNA in rodent islets exposed to high glucose concentrations (20) . To confirm these findings, we examined whether high glucose alters the expression of ALDOB in human islets isolated from organ donors. ALDOB protein was already detectable in the islets cultured at 5 mM glucose, and its level was significantly increased upon islets exposure to 15 mM or 20 mM glucose ( Fig. 3D and 3E ).
LCM-cut islet tissue is enriched in b-cells
The composition of LCM-cut tissue samples with respect to endocrine cell ratio was evaluated by analyzing insulin, glucagon, and somatostatin mRNA levels using quantitative RT-PCR (qRT-PCR) ( Table 1 ). The relative insulin mRNA level was 2500-fold higher than that of the housekeeping gene RPS13 and ;100-fold higher than glucagon and somatostatin mRNA levels. This proportion differs from the one observed in cultured human islets isolated from organ donors (19) . The insulin mRNA level of LCM-cut islet tissue, determined by the same qRT-PCR method, was 10-fold higher than that of isolated islets from organ donors, whereas the mRNA level of glucagon was 10-fold lower. This observation implies an enrichment of b-cells over a-cells when using the LCM as method for islet isolation.
Endocrine cell differentiation markers and a/b-cell areas do not correlate with HbA 1c b-cell dedifferentiation is a mechanism proposed to be, at least partly, responsible for reduced b-cell mass and impaired b-cell function (21) . The mRNA level of the b-cell differentiation marker PDX1 as well as other band a-cell-specific markers (MAFB, NEUROD1, and FOXO1) was remarkably similar between individuals and did not correlate with HbA 1c ( Supplemental  Fig. 4) .
To examine a possible association of b-and a-cell mass with glycemia, we assessed the area of insulin-and glucagon-immunostained islet cells in the pancreatic resections. Insulin immunostaining varied between 39% and 76% of total islet area, but there was no correlation with either HbA 1c or BMI (61.06 6 3.4% of total islet area in n = 10 subjects with HbA 1c ,6% and 60.56 6 2.7% of total islet area in n = 7 subjects with HbA 1c .6%) (Fig. 4A and 4B) . Similarly, glucagon immunostaining varied between 13% and 39% of islet area, but there was no correlation between a-cell area and HbA 1c or BMI (Fig. 4C and 4D ). The average a-cell area was 23.8 6 3.1% of total islet area in n = 9 subjects with HbA 1c ,6% and 28.7 6 1.7% of total islet area in n = 9 subjects with HbA 1c . 6%. Furthermore, the highly variable mRNA levels of insulin, glucagon, and somatostatin did also not correlate to HbA 1c , in our subjects at least (Fig. 4E-4G ). These results suggest that dedifferentiation and loss of b-cell mass are not major causes of the development of frequent hyperglycemic episodes (i.e., increased HbA 1c ).
Furthermore, no mRNA levels examined correlated with BMI, suggesting that obesity had no major impact on b-cell-specific gene expression in our cohort In summary, ALDOB expression is increased in islets from hyperglycemic subjects, an event that is associated with reduced insulin secretion.
Discussion
The current study shows that islet ALDOB mRNA levels negatively correlate with in vivo insulin secretion in humans. A direct effect of ALDOB on insulin secretion is suggested by the association of a common variant in ALDOB with insulin secretion evaluated using OGTT and hyperglycemic clamp studies in humans. Hyperglycemic clamp is the gold standard for the assessment of insulin secretion, allowing the estimation of insulin secretion independently from endogenous changes of blood glucose levels.
An upregulation of ALDOB and FAIM2 expression with hyperglycemia has been documented previously (11) . Despite the limited sample size in our study, the expressional alterations mirror recent data obtained from a larger set (n = 103) of LCMcut islet tissue (Supplemental Fig.  2) (11) .
In agreement with the transcriptome analysis of LCM-cut islet tissue, chronic exposure to high glucose augmented ALDOB protein in human islets isolated from organ donors. Similarly, in mature, functional rodent b-cells, AldoB expression is repressed, but strongly upregulated by hyperglycemia (7, 20, 23) . The confocal laser scanning imaging of immunostained pancreatic tissue and isolated human islet cells suggests that ALDOBexpressing islet cells are b-cells, as ALDOB and insulin signals were detected in the same cells. Single islet cell transcriptomics data suggest that only a minor fraction of b-cell population expresses ALDOB (Supplemental Fig. 6) (7, 18) . However, an increased expression of ALDOB was also detected in b-, d-, and g-cells from subjects with type 2 diabetes (Supplemental Fig. 7 ) (7). That dedifferentiation of b-cells underlies this process is unlikely, because the mRNA levels of b-cell-specific genes (PDX1, MAFB, INS, and NEU-ROD1), as well as b-and a-cell mass, were not different between patients with high and low HbA 1c . The transcripts of NANOG and POU5F1B were only modestly elevated in the hyperglycemic islets (data not shown), which, similarly to previous studies, suggests no considerable dedifferentiation of type 2 diabetic b-cells (9, 11).
Our observations suggest that increased expression of ALDOB in b-cells affects in vivo insulin secretion. A recent study with a b-cell-specific Raptor knockout mouse showed increased expression of AldoB in the islets and impaired glucose-induced insulin secretion (GIIS) and ATP production (24) . Similarly, b-cell-specific NeuroD1 knockout mice display impaired GIIS and upregulated AldoB in their b-cells (25) . Noteworthy, the juvenile, glucose-unresponsive b-cells express high levels of ALDOB and have high glycolytic flux and low oxidative metabolism (23, 26) . Thus, a chronic upregulation of ALDOB in adult b-cells might shift the glucose metabolism away from ATP production, an effect that could impair GIIS. ALDOB catalyzes the cleavage of fructose 1,6-bisphosphate and fructose 1-phosphate. The glycolytic intermediates DHAP and GA3P are primary sources for methylglyoxal production (27) . ALDOB seems to be involved in glucose-dependent overproduction of methylglyoxal (28) . Methylglyoxal accumulation predicts endothelial dysfunction in type 2 diabetes (29) . In b-cells, methylglyoxal-induced protein glycation and reactive oxygen species accumulation impair mitochondrial function and insulin secretion (30) . Further experiments are required to elucidate whether ALDOB mediates these events in human b-cells of subjects with type 2 diabetes.
The association of rs550915 in ALDOB with altered insulin secretion both in OGTT and hyperglycemic clamp studies indicates that ALDOB modulates insulin secretion ( Fig. 2A and 2B) . Data from the GTEx project indicate that this SNP is an expression quantitative trait locus. The minor allele of rs550915 is significantly associated with lower ALDOB expression in the tibial nerve (P = 0.000015; normalized effect size = 20.39). Islets are not specifically sampled in the GTEx project, but an association with expression in pancreas was not seen. However, rs550915 is a proposed multitissue expression quantitative trait locus in GTEx data, suggesting that it regulates gene expression of ALDOB in several tissues. In genome-wide association studies (with results accessed from www.type2diabetesgenetics.org), only one GWAS showed a nominal association of rs550915 with type 2 diabetes (31) . The discrepancy between effects on insulin secretion and type 2 diabetes prevalence could derive from compensatory glycemic effects of the variant in other tissues. ALDOB is prominently expressed in liver and kidney, two organs involved in glucose disposal and reabsorption. Effects of ALDOB in islets could be potentially offset by effects in these organs (32, 33) . In our study, the endogenous glucose handling was circumvented using a hyperglycemic clamp, which enabled us to investigate alterations of in vivo insulin secretion (Fig. 2B) .
The other prominently upregulated gene in hyperglycemic patients was the obesity-related gene FAIM2 (34) . FAIM2 expression in healthy islet cells is low (7) . Recent publications reported the upregulation and increased methylation of FAIM2 in type 2 diabetic islets, but its function in b-cells is currently unknown (11, 34, 35) . We also found no association between SNPs of FAIM2 and insulin secretion in our cohorts. As corroborated by the low expression level, this observation prompted us to attribute a rather minor role to FAIM2 in insulin secretion.
In contrast to the upregulation of ALDOB and FAIM2, expression of the b-cell proteins SLC2A2, FFAR4, TMEM37, and TMEM27 correlated negatively with hyperglycemia, confirming recent observations in type 2 diabetic islets (6, 11). The reduced SLC2A2 mRNA level points to a functional defect of b-cells (36) . Nonetheless, we found no correlation of SLC2A2 with in vivo insulin secretion. FFAR4, a long-chain fatty acids receptor, is expressed in b-, a-, and d-cells and augments glucagon and somatostatin secretion (7, 37, 38) . Again, we found no correlation with insulin secretion. Although a reduced expression of TMEM37, the regulatory g subunit of the voltage-gated Ca 2+ channel, was found in type 2 The housekeeping gene RPS13 was set to 1.
Abbreviation: Ct, threshold cycle.
diabetic islets, TMEM37 downregulation in INS-1E cells augmented insulin secretion (11) . The negative correlation between TMEM27 and HbA 1c confirms previous reports (11, 39) . TMEM27 supports GIIS and was proposed as a marker of b-cell mass (7, 40) . This study did not uncover a correlation of TMEM27 with insulin secretion, nor was b-cell area reduced in patients with high HbA 1c .
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